Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
26,748,295
-
Share change
-
+830,356
-
Total reported value
-
$43,867,000
-
Put/Call ratio
-
99%
-
Price per share
-
$1.64
-
Number of holders
-
39
-
Value change
-
+$1,288,968
-
Number of buys
-
13
-
Number of sells
-
24
Institutional Holders of GEMINI THERAPEUTICS INC - COM (GMTX) as of Q3 2022
As of 30 Sep 2022,
GEMINI THERAPEUTICS INC - COM (GMTX) was held by
39 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,748,295 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Atlas Venture Life Science Advisors, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Foresite Capital Management V, LLC, Foresite Capital Opportunity Management V, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, BOXER CAPITAL, LLC, CITADEL ADVISORS LLC, VANGUARD GROUP INC, and 5AM Venture Management, LLC.
This page lists
39
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.